The University of Texas Health Science Center at San Antonio
uthscsa.eduLive pipeline data from ClinicalTrials.gov, refreshed daily.
Total trials
434
Active
92
Phase 3
13
Total enrollment
54,518
Pipeline matrix
Showing 40 of 57 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Pioglitazone | — | — | — | 10 | |||
| Quetiapine | — | — | — | — | — | 2 | |
| Vancomycin | — | — | — | — | — | 1 | |
| Pioglitazone 45 mg | — | — | — | — | — | 1 | |
| Pimavanserin | — | — | — | — | — | 1 | |
| Tirzepatide | — | — | — | — | 2 | ||
| Sitagliptin | — | — | — | — | 2 | ||
| Dapagliflozin 10mg Tab | — | — | — | — | — | 1 | |
| Pioglitazone 15 MG and 30mg | — | — | — | — | — | 1 | |
| Metformin HCI XR | — | — | — | — | — | 1 | |
| Ketamine Hydrochloride | — | — | — | — | — | 1 | |
| Rapamycin | — | — | — | 7 | |||
| Ropivacaine | — | — | — | — | 2 | ||
| Sacituzumab Govitecan | — | — | — | — | 2 | ||
| Tremelimumab | — | — | — | — | — | 1 | |
| Durvalumab | — | — | — | — | — | 1 | |
| Bupropion Hydrochloride 150 MG | — | — | — | — | — | 1 | |
| Memantine | — | — | — | — | — | 1 | |
| Raloxifene | — | — | — | — | — | 1 | |
| Dupilumab | — | — | — | — | — | 1 | |
| IMG-7289 | — | — | — | — | — | 1 | |
| Lomustine | — | — | — | — | — | 1 | |
| Imipramine Hydrochloride | — | — | — | — | — | 1 | |
| Normal saline | — | — | — | — | — | 1 | |
| Empagliflozin 25 MG | — | — | — | 6 | |||
| Metformin | — | — | 7 | ||||
| Prednisone | — | — | — | — | 2 | ||
| Roflumilast | — | — | — | — | — | 2 | |
| Loncastuximab | — | — | — | — | — | 1 | |
| Rituximab | — | — | — | — | — | 1 | |
| Cyclophosphamide | — | — | — | — | — | 1 | |
| Vincristine | — | — | — | — | — | 1 | |
| Doxorubicin | — | — | — | — | — | 1 | |
| Avasopasem | — | — | — | — | — | 1 | |
| Empagliflozin 25 MG plus Pioglitazone placebo | — | — | — | — | — | 1 | |
| Pioglitazone 15 mg increased to 30 mg after 2 weeks plus Empagliflozin Placebo | — | — | — | — | — | 1 | |
| Empagliflozin 25 mg/d plus Pioglitazone | — | — | — | — | — | 1 | |
| Pioglitazone placebo + Empagliflozin placebo | — | — | — | — | — | 1 | |
| REMD-477 versus Placebo | — | — | — | — | — | 1 | |
| Rybelsus | — | — | — | — | — | 1 |
17 more active programs hidden
Next readouts
- 2023-12-20
- 2026-03-05
- 2026-04-30
- 2026-06
- 2026-07
- 2026-07-31
- 2026-08
- 2026-08
- 2026-08
- 2026-08
Top conditions
- Type 2 Diabetes18
- Breast Cancer15
- Aging12
- Schizophrenia12
- Bipolar Disorder11
- Prostate Cancer11
- Diabetes Mellitus, Type 29
- Posttraumatic Stress Disorder8
Frequently asked questions about The University of Texas Health Science Center at San Antonio
- How many clinical trials does The University of Texas Health Science Center at San Antonio have on ClinicalTrials.gov?
- The University of Texas Health Science Center at San Antonio is listed as the lead sponsor on 434 clinical trials in ClinicalTrials.gov, 92 of which are currently active (recruiting, enrolling, or ongoing).
- How many of The University of Texas Health Science Center at San Antonio's trials are in Phase 3?
- 13 of The University of Texas Health Science Center at San Antonio's trials are in Phase 3, spread across 57 active drug programs.
- What therapeutic areas does The University of Texas Health Science Center at San Antonio focus on?
- The University of Texas Health Science Center at San Antonio's most-studied conditions on ClinicalTrials.gov are Type 2 Diabetes, Breast Cancer, Aging, Schizophrenia, Bipolar Disorder.
- When are The University of Texas Health Science Center at San Antonio's next clinical trial readouts?
- The University of Texas Health Science Center at San Antonio has 10 upcoming primary-completion readouts tracked here; the soonest is “Hematology, IMG-7289, LSD1 (Lysine-Specific Demethylase 1) Inhibitor, Essential Thrombocythemia (ET), Ph 2”, expected around 2023-12-20.